CymaBay Therapeutics Inc. (NASDAQ:CBAY) went down by -6.28% from its latest closing price compared to the recent 1-year high of $9.06. The company’s stock price has collected -2.48% of loss in the last five trading sessions. Press Release reported on 04/05/21 that CymaBay Appoints Thomas Wiggans and Janet Dorling to Board of Directors
Is It Worth Investing in CymaBay Therapeutics Inc. (NASDAQ :CBAY) Right Now?
Plus, the 36-month beta value for CBAY is at 1.22. Opinions of the stock are interesting as 10 analysts out of 10 who provided ratings for CymaBay Therapeutics Inc. declared the stock was a “buy,” while 0 rated the stock as “overweight,” 0 rated it as “hold,” and 0 as “sell.”
The average price from analysts is $12.00. CBAY currently public float of 65.19M and currently shorts hold a 13.05% ratio of that float. Today, the average trading volume of CBAY was 1.08M shares.
CBAY’s Market Performance
CBAY stocks went down by -2.48% for the week, with a monthly drop of -4.63% and a quarterly performance of -19.07%, while its annual performance rate touched 144.63%. The volatility ratio for the week stands at 5.71% while the volatility levels for the past 30 days are set at 4.76% for CymaBay Therapeutics Inc.. The simple moving average for the period of the last 20 days is -1.90% for CBAY stocks with a simple moving average of -28.57% for the last 200 days.
Analysts’ Opinion of CBAY
Many brokerage firms have already submitted their reports for CBAY stocks, with H.C. Wainwright repeating the rating for CBAY by listing it as a “Buy.” The predicted price for CBAY in the upcoming period, according to H.C. Wainwright is $13 based on the research report published on August 04th of the previous year 2020.
Piper Sandler, on the other hand, stated in their research note that they expect to see CBAY reach a price target of $12. The rating they have provided for CBAY stocks is “Overweight” according to the report published on July 31st, 2020.
H.C. Wainwright gave a rating of “Buy” to CBAY, setting the target price at $9 in the report published on May 26th of the previous year.
CBAY Trading at -7.43% from the 50-Day Moving Average
After a stumble in the market that brought CBAY to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -52.21% of loss for the given period.
Volatility was left at 4.76%, however, over the last 30 days, the volatility rate increased by 5.71%, as shares sank -7.08% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -18.61% lower at present.
During the last 5 trading sessions, CBAY fell by -2.48%, which changed the moving average for the period of 200-days by +21.63% in comparison to the 20-day moving average, which settled at $4.40. In addition, CymaBay Therapeutics Inc. saw -24.56% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for CBAY
The total capital return value is set at -32.02, while invested capital returns managed to touch -30.71. Equity return is now at value -31.90, with -29.70 for asset returns.
Based on CymaBay Therapeutics Inc. (CBAY), the company’s capital structure generated 1.22 points at debt to equity in total, while total debt to capital is 1.21. Total debt to assets is 1.13, with long-term debt to equity ratio resting at 0.88. Finally, the long-term debt to capital ratio is 0.87.
The liquidity ratio also appears to be rather interesting for investors as it stands at 15.38.